J. Goldman & Co LP Sells 60,064 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

J. Goldman & Co LP lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 94.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,373 shares of the biopharmaceutical company's stock after selling 60,064 shares during the period. J. Goldman & Co LP's holdings in Gilead Sciences were worth $312,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. Jacobs Levy Equity Management Inc. boosted its position in shares of Gilead Sciences by 27.6% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 648,386 shares of the biopharmaceutical company's stock worth $59,891,000 after buying an additional 140,095 shares during the period. Kaizen Financial Strategies acquired a new position in Gilead Sciences during the 4th quarter worth $222,000. Guardian Wealth Advisors LLC NC grew its stake in shares of Gilead Sciences by 22.9% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 3,227 shares of the biopharmaceutical company's stock worth $298,000 after purchasing an additional 601 shares in the last quarter. Gotham Asset Management LLC increased its holdings in shares of Gilead Sciences by 0.3% during the fourth quarter. Gotham Asset Management LLC now owns 256,041 shares of the biopharmaceutical company's stock valued at $23,651,000 after purchasing an additional 873 shares during the period. Finally, Graham Capital Management L.P. acquired a new stake in Gilead Sciences in the fourth quarter worth about $1,744,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $2.16 during trading hours on Friday, reaching $102.50. The stock had a trading volume of 6,395,303 shares, compared to its average volume of 7,649,762. The company has a market cap of $127.63 billion, a price-to-earnings ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The business's fifty day moving average is $105.99 and its two-hundred day moving average is $99.58. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.08%. Gilead Sciences's dividend payout ratio is 66.53%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GILD. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. BMO Capital Markets upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Finally, Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 25,429 shares of company stock valued at $2,894,445. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.